BACKGROUND: Children with acute lymphoblastic leukemia (ALL) can develop reduced bone mineral density (BMD). However, data from patients who received treatment on a frontline regimen without cranial irradiation are limited, and no genome-wide analysis has been reported. METHODS: Lumbar BMD was evaluated by quantitative computed tomography at diagnosis, after 120 weeks of continuation therapy, and after 2 years off therapy in pediatric patients with ALL (ages 2-18 years at diagnosis) who were treated on the St. Jude Total XV Protocol. Clinical, pharmacokinetic, and genetic risk factors associated with decreased BMD Z-scores were evaluated. RESULTS: The median BMD Z-score in 363 patients was 0.06 at diagnosis, declined to 21.08 at week 120, but partly recovered to 20.72 after 2 years off therapy; BMD in patients with low BMD Z-scores at diagnosis remained low after therapy. Older age (10 years vs 2-9.9 years at diagnosis; P <.001), a higher BMD Z-score at diagnosis (P 5.001), and a greater area under the plasma drug concentration-time curve for dexamethasone in weeks 7 and 8 of continuation therapy (P 5.001) were associated with a greater decrease in BMD Z-score from diagnosis to week 120. Single-nucleotide polymorphisms in 2 genes important in osteogenesis and bone mineralization (COL11A1 [reference single-nucleotide polymorphism rs2622849]; P 5 2.39 3 10 27 ] and NELL1 [rs11025915];
INTRODUCTION
The survival rate for acute lymphoblastic leukemia (ALL) has increased to approximately 90% as a result of the introduction of risk-based treatment and improved supportive care. 1 However, ALL treatment itself can have adverse effects. In healthy children, bone mineral density (BMD) continues to increase until early in the third decade of life, 2 but children with ALL can develop reduced BMD because of the disease, its treatment, nutritional deficiencies, and/or physical inactivity. [3] [4] [5] [6] Glucocorticoids decrease bone formation by promoting apoptosis of osteoblasts and osteocytes, increasing bone resorption and disturbing the calcium balance by reducing intestinal absorption of calcium and increasing its renal excretion. 3 Endocrine abnormalities after cranial irradiation also contribute to bone morbidity. 3 Although we have demonstrated that prophylactic cranial irradiation can safely be omitted from the treatment of childhood ALL, 7 there are only limited data on BMD in patients who receive treatment on a regimen without cranial irradiation.
Candidate gene studies have identified several single-nucleotide polymorphisms (SNPs) associated with low BMD in patients with ALL, including those in the vitamin D receptor (VDR) 5 0 -end (Cdx-2/GATA polymorphism) haplotype 3 (P 5 .01), 8 the genes encoding methylenetetrahydrofolate reductase (the MTHFR 677 thymine [T] allele) and methionine synthase reductase (the MTRR 66 guanine [G] allele; P .01 with 2 or more risk alleles), 9 CRHR1 (the G allele of reference SNP rs1876828; P 5 .02 for boys), 10 and RAPGEF5 (the T allele of rs6461639; P 5 .016). 11 However, there has been no genome-wide analysis of low BMD in patients with ALL. Therefore, we evaluated clinical, pharmacokinetic, and genetic risk factors influencing BMD, especially those associated with a decline in BMD Z-scores during therapy, in children with ALL who received treatment on a contemporary protocol without cranial irradiation.
MATERIALS AND METHODS

Patients
Pediatric patients ages 1 to 18 years at diagnosis of ALL were enrolled on the Total XV protocol (clinicaltrials.gov identifier NCT00137111) at St. Jude Children's Research Hospital (St. Jude) from 2000 to 2007. 7 Patients who were between ages 1 and 2 years at diagnosis and those with Down syndrome were excluded; and those who died, experienced relapse, or underwent hematopoietic stem cell transplantation (HSCT) were removed from analyses involving subsequent BMD evaluations. The study was approved by the St. Jude Institutional Review Board.
Treatment
Total XV therapy and risk classification are described elsewhere. 7 Patients received prednisone at 40 mg/m 2 daily for 28 days during induction and 5-day dexamethasone pulses every 4 weeks during continuation weeks 1 through 100 at 8 mg/m 2 daily for low-risk (LR) patients and 12 mg/m 2 daily for standard/high-risk (S/HR) patients. During reinduction I (weeks 7-9 of continuation) and II (weeks [17] [18] [19] , all patients received dexamethasone at 8 mg/m 2 daily on days 1 through 8 and days 15 through 21, resulting in a cumulative prednisone dose of 1120 mg/m 2 (for all patients) plus a dexamethasone dose of 1160 mg/m 2 (for LR patients) or 1620 mg/m 2 (for S/ HR patients). 7, 12 During remission induction, patients received 6 doses of L-asparaginase (10,000 U/m 2 per dose) during the first 19 days, and patients who had minimal residual disease (MRD) 1% on day 19 received 3 more doses. LR patients received 9 doses of Lasparaginase (10,000 U/m 2 per dose) during each reinduction, whereas S/HR patients received 19 weekly doses (25,000 U/m 2 per dose) starting in week 1. Consolidation treatment consisted of high-dose methotrexate (a targeted, steady-state concentration of 33 lM for LR patients and 65 lM for S/HR patients) in 4 courses over 8 weeks with daily mercaptopurine. No cranial irradiation was used.
Bone Mineral Density
Quantitative computed tomography (QCT) data on vertebral trabecular BMD were obtained for the lumbar spine (L1/L2) at diagnosis, after 120 weeks of continuation therapy (when female patients completed treatment), after 146 weeks of continuation therapy (for male patients only, who then completed all treatment), and 2 years after completing therapy. Data were obtained with a Siemens SOMATOM-Plus spiral computed tomography (CT) scanner (Siemens, Iselin, NY) and Mindways QCT calibration phantoms and software (Mindways Software, Austin, TX), as previously reported. 13 References for vertebral BMD Z-scores based on age and sex were provided by the manufacturer of the QCT software (Mindways Software).
14 The 2 vertebral BMD measurements were averaged, and the BMD Z-scores were used for analysis. In this study, a BMD Z-score less than 21.5 was considered an indication of low BMD.
Dexamethasone and Methotrexate Pharmacokinetics and Cortisol and Lipid Levels
Blood samples for measuring dexamethasone levels were drawn before and after the morning dexamethasone doses (at 1, 2, 4, and 8 hours) on days 1 and 8 of reinduction I (in weeks 7 and 8 of continuation treatment). 12, 15 Dexamethasone pharmacokinetic parameters were estimated by fitting a 1-compartment model to the plasma concentration-time data by using maximum a posteriori probability estimation, as implemented in ADAPT II (Biomedical Simulations Resource, Los Angeles, CA). Plasma methotrexate concentrations were measured using a fluorescence polarization immunoassay (TDxFLx System; Abbott, Chicago, IL) before infusion then at 0.5 to 6 hours, 23 hours, and 42 hours after the start of methotrexate infusion. 16, 17 Pharmacokinetic parameters were estimated with a 2-compartment, first-order model in ADAPT II.
Heparinized blood samples were drawn on day 1 of week 7 of the continuation phase. 12 Serum cortisol levels were determined by high-performance liquid chromatography. High-density and low-density lipoproteins, cholesterol, and triglycerides were measured with a colorimetric enzymatic assay on a Cobas Integra system (Roche Diagnostics, Florham Park, NJ).
Statistical Analysis
Associations of clinical characteristics with BMD Z-scores at each time point were evaluated using the rank-sum test or the Spearman correlation test. Associations of BMD Zscore categories (0, from 21.5 to <0, and <21.5) between 2 time points were tested with the chi-square test. To account for baseline data and the lack of a race-specific BMD Z-score reference, the analyses for the associations of clinical characteristics and BMD Z-score changes between 2 time points (from diagnosis to week 120 and from week 120 to 2 years off therapy) were adjusted for baseline BMD Z-score (at diagnosis or week 120) and race (white, black, or other) in the linear regression model. The BMD Z-score categories (21.5 vs <21.5) at week 120 and 2 years off therapy were modeled in logistic regression with clinical characteristics as predictors, adjusting for baseline BMD Z-score and race. The independent effect of each factor with a P value < .10 was determined by multivariable analysis. The associations of dexamethasone and methotrexate pharmacokinetics and albumin, lipid, and cortisol levels with changes in BMD Z-scores from diagnosis to week 120 were evaluated after adjustments for BMD Z-score at diagnosis and race and after additional adjustments for age and treatment risk in the multiple linear regression framework. In this analysis, the area under the plasma drug concentration-time curve (AUC) for dexamethasone was evaluated for each increment of 50 nM*hour, and the triglyceride, total cholesterol, LDL, and HDL levels were considered for each increment of 20 mg/dL. Multivariable analysis was performed with factors identified by best-set model selection analysis using the Akaike information criterion (AIC). Statistical and computational analyses were performed using "R" Version 3.3.1 software (R Foundation for Statistical Computing, Vienna, Austria; www.r-project.org) and SAS software (version 9.4; SAS Institute, Cary, NC).
Genome-Wide Association Study
Germline DNA samples were collected at remission and genotyped with the Affymetrix GeneChip Human Mapping 100K and 500K Array Sets (Affymetrix, Inc, Santa Clara, CA). We studied 481,281 SNP genotypes after excluding 51,271 SNPs because of a low minor-allele frequency (<1%) or a poor call rate (<95%).
For this genome-wide association study (GWAS), SNP genotypes were evaluated for associations with BMD Z-score changes from diagnosis to week 120 of continuation treatment with significance levels of P < 1 3 10
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, as selected by information-profiling criteria after adjustments for age, treatment risk, BMD Z-score at diagnosis, and genetic ancestry. The Spearman rank-correlation test was used to evaluate the associations between SNPs that were significantly associated with BMD Z-score changes from diagnosis to week 120 and the dexamethasone AUC. 18 
RESULTS
Patients and QCT Data
Of the 409 patients who received treatment, 26 between ages 1 and 2 years at diagnosis, 10 with Down syndrome were excluded, and 10 had not had a QCT evaluation of their BMD, leaving 363 patients who had undergone at least 1 QCT evaluation ( Fig. 1 and Supporting Table 1 ; see online supporting information). Table 1 lists the cross-sectional BMD Z-scores and their categories at each time point. The median BMD Zscore was 0.06 at diagnosis, decreased to 21.08 at week 120, but improved to 20.72 at 2 years after therapy. There were no differences in BMD Z-scores between male and female patients. We note that, although other clinical characteristics did not differ, the available BMD Z-scores at diagnosis and at week 120 in 232 patients who had a QCT examination at 2 years off therapy were lower than those in 72 patients who did not have a QCT examination (Supporting Table 2 ; see online supporting information). The median Z-scores at diagnosis were 20.05 (range, 23.27 to 3.56) for 216 patients who had a QCT examination and 0.30 (range, 22.12 to 2.68) for 66 patients who did not (P 5 .009). The median Z-scores at week 120 were 21.13 (range, 25.93 to 2.05) for 219 patients who had a QCT examination and 20.92 (range, 24.73 to 1.31) for 58 patients who did not (P 5 .043). When the BMD Z-scores were categorized as 0, 21.5 to <0, or <21.5, the percentage of patients with a BMD Z-score of <21.5 was 6.5%, 37.8%, and 25.4% at diagnosis, week 120, and 2 years off therapy, respectively. There were significant associations in the BMD Z-score categories between any 2 time points (P < .001 for all 3 association tests); most patients who had BMD Z-scores less than 21.5 at diagnosis remained in the same category at the subsequent time points (Supporting Table 3 ; see online supporting information). However, 14 of 108 patients (13.0%) with BMD Z-scores 0 and 31 of 95 patients (32.6%) with BMD Z-scores 21.5 but <0 at diagnosis had BMD Z-scores <21.5 at 2 years off therapy.
Clinical Characteristics Associated With QCT BMD Z-Score Values
Supporting Table 4 and Supporting Figure 1 provide details of the associations between BMD Z-scores and presenting clinical factors (see online supporting information). At diagnosis, patients aged 10 years had a median BMD-Z-score of 0.50, which was higher than that of the normal controls, and those ages 2 to 9.9 years had a median Z-score of 20.09, which was comparable to that of the controls. In multivariable analysis, age 10 years (vs ages 2-9.9 years) was significantly associated with a higher BMD Z-score (P 5 .030). Age 10 years at diagnosis and a lower BMD Z-score at diagnosis were significantly associated with a lower BMD Z-score at week 120 (P < .001 for both). Lower BMD Z-scores at week 120 correlated with lower BMD Z-scores at 2 years after therapy (P < .001). Table 2 adjustment for baseline BMD Z-score and race. In multivariable analysis, age 10 years at diagnosis, compared with ages 2 to 9.9 years, and a greater decrease in height Z-score from diagnosis to week 120 were significantly associated with a greater decline in BMD Z-score from diagnosis to week 120 (P < .001 and P 5 .009, respectively). Patients aged 10 years at diagnosis had a significantly greater increase in BMD Z-score from week 120 to Abbreviations: BMI, body mass index; CI, confidence interval; CNS, central nervous system; WBC, white blood cell count. a Data are adjusted for baseline bone mineral density Z-scores and race. Data for 2 years off therapy from week 120 also are adjusted for sex. b Multivariable analysis was performed to determine the independent effect of each individual factor that had a P value < .10. 2 years off therapy than did those ages 2 to 9.9 years at diagnosis (P < .001).
When clinical characteristics associated with a low BMD Z-score (<21.5) were evaluated after adjustment for baseline BMD Z-score and race, patients aged 10 years at diagnosis were at significantly higher risk for a low BMD Z-score at week 120 compared with patients ages 2 to 9.9 years at diagnosis (P 5 .003) (Supporting Table 5 ; see online supporting information).
Association of Dexamethasone and Methotrexate Pharmacokinetics and Albumin and Lipid Levels With QCT BMD Z-Scores at Week 120
We evaluated the associations of changes in BMD Zscore from diagnosis to week 120 with dexamethasone and methotrexate pharmacokinetics and with albumin, lipid, and cortisol levels adjusted for BMD Z-score at diagnosis and race, and also with additional adjustments for age at diagnosis and treatment risk, by using a multiple linear regression model (Table 3 ). In the latter model, the average AUCs for dexamethasone in continuation weeks 7 and 8 (P < .001) and triglyceride (P 5 .021) and cholesterol (P 5 .018) levels in week 7 were negatively associated with changes in BMD Zscore, and the albumin level in week 7 (P 5 .017) was positively associated with such changes. These results suggest that larger dexamethasone AUCs, higher triglyceride and cholesterol levels, and lower albumin levels result in a greater decrease in BMD Z-score from diagnosis to week 120.
Multivariable Analysis of Factors Associated With BMD Z-Scores at Week 120
To evaluate factors that were significant for changes in BMD Z-score from diagnosis to week 120 in multivariable analysis, we performed best-set model selection analysis with the AIC by using the age group, leukemia risk, BMD Z-score at diagnosis, race, lineage, Z-score changes for height and body mass index from diagnosis to week 120, average of the week 7 and 8 dexamethasone AUCs, average methotrexate AUCs during consolidation, and levels of albumin, triglyceride, and total cholesterol in week 7 of continuation therapy (Supporting Table 6 ; see online supporting information). The best model fit (AIC 649.924) included age group, leukemia risk, BMD Zscore at diagnosis, race, average of the week 7 and 8 dexamethasone AUCs, average methotrexate AUCs during consolidation, and total cholesterol level in week 7. In multivariable analysis with these factors, age 10 years at diagnosis (P < .001), higher BMD Z-score at diagnosis (P 5 .001), and greater average of the week 7 and 8 dexamethasone AUCs (P 5 .001) were associated with a greater decrease in BMD Z-score from diagnosis to week 120 (Table 4 ).
Genomic Study
We investigated which of 481,281 germline SNP genotypes were associated with BMD Z-score changes from diagnosis to continuation week 120 ( Fig. 2A) . Table 5 lists the 38 SNPs that had P values < 1.0 3 10
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, of which 19 were annotated to 16 genes.
Across the genome, the strongest association of an SNP with BMD Z-score changes from diagnosis to week 120 was observed for an SNP in the collagen type XI a 1 chain (COL11A1) gene (rs2622849) in chromosome 1p21.1 (Fig. 2B) . The T allele of this intronic SNP was associated with a significant decrease in BMD Z-score (coefficient, 21.071; P 5 2.39 3 10 27 ) ( Table 5) . Similarly, the adenine (A) allele of the neural epidermal growth factor-like 1 (NELL1) SNP (rs11025915) (Fig. 2C ) was associated with a decrease in BMD Z-score (coefficient, 21.306; P 5 4.07 3 10 26 ). Because the dexamethasone AUC was negatively associated with BMD Z-score changes, we evaluated the associations of 38 germline SNP genotypes that were significant for a decrease in BMD Z-score from diagnosis to week 120 with larger dexamethasone AUCs. Five SNPs (13.2%) had P values < .05 (Table 5 ), including NELL1 (the A allele of rs11025915; P 5 .003) and nuclear factor IB (NFIB) (the G allele of rs16931403; P 5 .024). 
DISCUSSION
The current study demonstrated, in patients with ALL who received treatment without cranial irradiation, BMD decreased significantly by week 120 of continuation therapy and partly recovered by 2 years off therapy. The BMD in most patients who had low BMD Z-scores (<21.5) at diagnosis remained low at week 120 and 2 years off therapy. BMD Z-scores significantly decreased from diagnosis to week 120 in older patients and in those who had higher BMD Z-scores at diagnosis, greater dexamethasone exposure, and/or SNPs identified by a GWAS. The median BMD Z-score at diagnosis in our patients (0.06) was comparable to that in the general population, but the scores ranged from 23.27 to 3.56. Because of leukemia cell proliferation in the bone marrow and cytokine-mediated osteoclast activity, children with ALL can present with low BMD Z-scores at diagnosis, 4 which are associated with persistently low BMD Z-scores during and after therapy. BMD Z-scores at diagnosis were significantly higher in patients aged 10 years at diagnosis; however, these patients are considered to have a higher leukemia risk and typically receive higher and more intense doses of chemotherapeutic agents, which disturb bone mineralization, resulting in a greater decline in BMD over the course of therapy. Among the clinical characteristics, a decline in height Z-score from diagnosis to week 120 was associated significantly with a decline in BMD Z-score in the same period. BMD and height increase significantly during puberty, 2, 19 and normal accruals might have been compromised and/or delayed during chemotherapy, causing significantly more patients in this age group to have a BMD Z-score less than 21.5 at week 120. The associations of older age and low BMD Z-score at diagnosis with lower BMD during continuation therapy have been described. 20 A larger dexamethasone AUC, which is a known factor in bone morbidity, 12 was significantly associated with a decrease in BMD Z-score during therapy. Although glucocorticoids play important roles in BMD deficits, other chemotherapeutic agents can contribute to such deficits. Low albumin and high triglyceride and total cholesterol levels in week 7 of continuation were significantly associated with a decrease in BMD Z-score, although these factors did not remain significant with the AIC and/or in multivariable analysis. Lower albumin levels and older age are associated with a larger dexamethasone AUC. 12 Hypoalbuminemia is caused by the administration of asparaginase, which is more frequently used in older patients.
Hypertriglyceridemia and hypercholesterolemia, which occur frequently during ALL therapy, are associated with asparaginase activity, because asparaginase can inhibit lipoprotein lipase activities. 12 Thus, asparaginase may indirectly cause a decline in BMD by increasing the dexamethasone AUC. Methotrexate reportedly reduces the proliferation of preosteoblasts and osteoblasts, increases the proliferation of osteoclasts, 21 and contributes to calcium imbalance by interfering with renal function. 22 However, the methotrexate AUC did not remain significant in our current multivariable analysis. Abbreviations: AUC, area under the plasma drug concentration2time curve; BMD, bone mineral density; C9orf72, chromosome 9 open reading frame 72; COL11A1, collagen type XI a 1 chain; DLG2, discs large MAGUK scaffold protein 2; IRF8, interferon regulatory factor 8; LOC100129666, similar to chimerin (chimaerin) 1; MGC45800, uncharacterized LOC90768; MUC16, mucin 16, cell surface associated; NCAM1, neural cell adhesion molecule 1; NELL1, neural epidermal growth factor-like 1; NFIB, nuclear factor IB; OLFML2B, olfactomedin-like 2B; PPTC7, PTC7 protein phosphatase homolog; RNF130, ring finger protein 130; SNP ID, reference single-nucleotide polymorphism (rs) identifier according to the dbSNP database; SRGAP3, SLIT-ROBO Rho GTPase activating protein 3; TLL1, tolloid like 1; ZNF496, zinc finger protein 496. a Analyses were adjusted for age, genetic ancestry, treatment risk, and BMD Z-score at diagnosis.
In the GWAS, the 2 SNPs most associated with BMD Z-score changes from diagnosis to week 120 were those in the COL11A1 and NFIB genes, which are important in osteogenesis and bone mineralization. COL11A1 encodes the a-1 chain of type XI collagen, which is composed of 3 a-chain products from COL11A1, COL11A2, and COL2A1. 23 The phenotypes of type XI collagenopathies caused by COL11A1 mutations in humans are heterogeneous and are associated not only with syndromes characterized by myopia, midfacial retrusion, and micrognathia but also with skeletal dysplasia. NELL1 is a secreted protein whose expression promotes osteoblast cell differentiation and terminal mineralization and inhibits osteoclast-induced bone resorption. 24 NELL-1 overexpression results in craniosynostosis, whereas decreased NELL-1 expression leads to skeletal undermineralization. Administration of recombinant NELL-1 improves BMD in rodents. NELL-1 and NFIB are associated with larger dexamethasone AUCs. NFIB is a cellular transcription factor that plays critical roles in osteoblast proliferation, differentiation, and survival and that regulates cartilage development. 25 Nfib and the glucocorticoid receptor gene Nr3c1 coregulate genes related to lung maturation, 26 and NFIB and glucocorticoid receptor are critically involved in the development of milk-secreting alveolar epithelium in the mammary gland. 27 Such interactions may alter dexamethasone pharmacokinetics during chemotherapy.
In our study, BMDs partly recovered after patients completed therapy. This result must be interpreted cautiously, because patients who underwent a QCT examination at 2 years off therapy had lower BMD Z-scores at diagnosis and week 120 compared with those who did not undergo a QCT examination, although there were no differences in other clinical characteristics. However, among patients who were evaluated by QCT at 2 years off therapy, the median BMD Z-score at 2 years off therapy (20.72) was still lower than that at diagnosis (20.05) and improved only partially from that score at week 120 (21.13) .
Survivors who receive treatment without cranial irradiation have better BMD recovery after chemotherapy compared with those who undergo irradiation. 3, 28 We evaluated the clinical factors associated with changes in BMD Z-score from week 120 to 2 years off therapy. It is noteworthy that, at 2 years off therapy, the BMD Z-scores increased to a significantly greater extent in older patients than in younger patients, who did not lose BMD during therapy or gain it after therapy as did older patients. Although there was no significant difference between the age groups, the median BMD Z-score in younger patients was 20.79, compared with 20.26 in older patients. Patients who had low BMD Z-scores at diagnosis had low BMD Z-scores not only at week 120 but also at 2 years off therapy. Younger patients who have low BMD Z-scores at diagnosis may require long-term follow-up, and it needs to be determined whether they experience a typical physiologic BMD increase after the age of 10 years. In addition, patients with BMD Z-scores of 21.5 or less at 2 years off therapy require close observation and/or intervention.
Interventions to prevent bone loss during ALL therapy may include dietary counseling/supplementation to ensure adequate vitamin D and calcium intake, 13 dexamethasone dose adjustment, and/or weight-bearing exercise. 29 However, persuading children and families to adhere to dietary modifications may be particularly challenging during ALL treatment. For adolescent and young adult survivors of ALL, supplementation with cholecalciferol and calcium conferred no additional benefit. 13 Pharmacokinetics-based adjustment of the dexamethasone doses may compromise the desired antileukemia response. Weight-bearing exercise at the frequency and intensity necessary for optimal bone growth is difficult during ALL therapy and is discouraged for patients with osteonecrosis (another chemotherapy-related bone toxicity in ALL). However, it has been reported that lowmagnitude, high-frequency mechanical stimulation improves or prevents BMD loss in postmenopausal women, 30 patients with dystrophinopathies, 31 and children who have undergone cancer therapy. 32 Because the patients only need to stand on a vibrating platform for 10 minutes twice each day, the use of low-magnitude, highfrequency mechanical stimulation to counter BMD loss during cancer therapy should be evaluated, and we are performing a placebo-controlled, randomized study in patients with ALL (NCT03117751). The efficacy of pharmacologic agents, such as bisphosphonate and receptor activator of nuclear factor-jB ligand (RANKL) inhibitor, has been reported in pilot trials, [33] [34] [35] and these agents may be beneficial if a successful treatment approach is determined in the context of ALL therapy.
None of the SNPs that we evaluated reached genome-wide significance (<5 3 10
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), probably because of the limited sample size; therefore, an additional study that includes a replication cohort will be required to confirm our findings. However, to our knowledge, this is the first GWAS to investigate genetic risk factors for BMD changes in patients with ALL, and 2 identified SNPs play critical roles in bone development. Bone density can be evaluated by either QCT or dual x-ray absorptiometry (DXA). Both approaches have strengths and weaknesses, although DXA is more widely used. 36, 37 DXA can assess the BMD of the whole body or of individual areas and defines BMD Z-scores by race-matched references in addition to age and sex. However, DXA measures a 2-dimensional area, and the volumetric result is generated by calculation, which may lead to an underestimation of BMD in smaller bones. The BMD determination by QCT is volumetric and independent of bone size, and it is not hampered by longitudinal bone growth. Furthermore, the QCT software can correct for the curves in patients with scoliosis. In the current study, we presented the trabecular BMD, because trabecular bone is much more metabolically active than cortical bone and is considered a more sensitive indicator of skeletal metabolism and response to stresses and interventions. 38 Because the QCT reference data are based on the white population 14 and the BMD Z-scores in black patients tended to be higher than those in white patients, 39 we adjusted the data for BMD Z-score changes and categories with respect to race. Because baseline BMD Z-scores were significantly associated with subsequent values, we also adjusted these data to account for baseline values. Although we did not collect bone-fracture data prospectively, low BMD measured by QCT or DXA is associated with future fracture risk. 20, 40, 41 In conclusion, BMD Z-scores decrease significantly in children who receive contemporary therapy for ALL without cranial irradiation; and, in many cases, the scores do not fully recover by 2 years off therapy. Early recognition of changes in BMD may facilitate the development of strategies to optimize bone health, especially in patients who have the risk factors identified in this study.
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